Drug Type T cell engagers (TCE) |
Synonyms NRM 823, NRM823 |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of Esophagus | Phase 1 | - | 01 Oct 2025 | |
Endometrial Carcinoma | Phase 1 | - | 01 Oct 2025 | |
Esophageal Squamous Cell Carcinoma | Phase 1 | - | 01 Oct 2025 | |
Gastroesophageal junction adenocarcinoma | Phase 1 | - | 01 Oct 2025 | |
Non-Small Cell Lung Cancer | Phase 1 | - | 01 Oct 2025 | |
Ovarian Cancer | Phase 1 | - | 01 Oct 2025 | |
Squamous Cell Carcinoma of Head and Neck | Phase 1 | - | 01 Oct 2025 | |
stomach adenocarcinoma | Phase 1 | - | 01 Oct 2025 | |
Triple Negative Breast Cancer | Phase 1 | - | 01 Oct 2025 | |
Uterine Cervical Cancer | Phase 1 | - | 01 Oct 2025 |